You are correct, it hit my target and now I am out. I nearly doubled my money and I didnt really see any near term price appreciation happening so I took my money out to find a better investment. What a ride though! I still love the company and I bet in time the SP will rise more, but I just wanted to play the Kuvan rally and get out. There are too many other better plays right now to keep my money in BMRN. Plus I have a new policy to avoid all biotech stocks... just too risky for me.
Best of luck to you! Thanks for contributing to this board.
Best of luck to you! Thanks for contributing to this board.
Recent BMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 10:05:02 PM
- BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia • PR Newswire (US) • 05/20/2026 08:20:00 PM
- BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency • PR Newswire (US) • 05/18/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/11/2026 09:01:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 05:17:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 05:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:07:23 PM
- BioMarin Reports First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 05/04/2026 08:05:00 PM
- BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting • PR Newswire (US) • 05/02/2026 07:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 12:45:12 PM
- BioMarin Completes Acquisition of Amicus Therapeutics • PR Newswire (US) • 04/27/2026 12:44:00 PM
- BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET • PR Newswire (US) • 04/27/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:20:56 PM
- BioMarin Announces Board Leadership Transition • PR Newswire (US) • 04/21/2026 08:23:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 08:21:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:19:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:53:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:50:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:48:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:34:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 05:42:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:48:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:43:06 AM
